scholarly journals HIV-1 Capture and Antigen Presentation by Dendritic Cells: Enhanced Viral Capture Does Not Correlate with Better T Cell Activation

2012 ◽  
Vol 188 (12) ◽  
pp. 6036-6045 ◽  
Author(s):  
Maria T. Rodriguez-Plata ◽  
Alejandra Urrutia ◽  
Sylvain Cardinaud ◽  
Maria J. Buzón ◽  
Nuria Izquierdo-Useros ◽  
...  
Keyword(s):  
Dendritic Cells ◽  
T Cell ◽  
Antigen Presentation ◽  
T Cell Activation ◽  
Cell Activation ◽  
Hiv 1

scholarly journals HIV-1 capture and antigen presentation by dendritic cells: enhanced viral capture does not correlate with better T-Cell activation

Retrovirology ◽  
2012 ◽  
Vol 9 (S2) ◽  
Author(s):  
M Rodriguez-Plata ◽  
A Urrutia ◽  
S Cardinaud ◽  
M Buzon ◽  
N Izquierdo-Useros ◽  
...  
Keyword(s):  
Dendritic Cells ◽  
T Cell ◽  
Antigen Presentation ◽  
T Cell Activation ◽  
Cell Activation ◽  
Hiv 1

scholarly journals Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation

2013 ◽  
Vol 43 (10) ◽  
pp. 2554-2565 ◽  
Author(s):  
Rodney A. Rosalia ◽  
Esther D. Quakkelaar ◽  
Anke Redeker ◽  
Selina Khan ◽  
Marcel Camps ◽  
...  
Keyword(s):  
Dendritic Cells ◽  
T Cell ◽  
Antigen Presentation ◽  
T Cell Activation ◽  
Cell Activation ◽  
Synthetic Long Peptides ◽  
Better Than

scholarly journals Targeting HIV-1 Gag into the Defective Ribosomal Product Pathway Enhances MHC Class I Antigen Presentation and CD8+T Cell Activation

2007 ◽  
Vol 180 (1) ◽  
pp. 372-382 ◽  
Author(s):  
Andreas Goldwich ◽  
Sabine S. C. Hahn ◽  
Sandra Schreiber ◽  
Stefanie Meier ◽  
Eckhart Kämpgen ◽  
...  
Keyword(s):  
T Cell ◽  
Antigen Presentation ◽  
Mhc Class I ◽  
T Cell Activation ◽  
Cell Activation ◽  
Cd8 T Cell ◽  
Class I ◽  
Mhc Class I Antigen ◽  
Hiv 1

scholarly journals Acquisition and presentation of follicular dendritic cell–bound antigen by lymph node–resident dendritic cells

2010 ◽  
Vol 208 (1) ◽  
pp. 135-148 ◽  
Author(s):  
Megan L. McCloskey ◽  
Maria A. Curotto de Lafaille ◽  
Michael C. Carroll ◽  
Adrian Erlebacher
Keyword(s):  
Dendritic Cells ◽  
Lymph Node ◽  
T Cell ◽  
Antigen Presentation ◽  
T Cell Activation ◽  
Immune Complexes ◽  
Cell Activation ◽  
Follicular Dendritic Cell ◽  
Affinity Maturation ◽  
Follicular Dendritic

Follicular dendritic cells (DCs [FDCs]) are prominent stromal cell constituents of B cell follicles with the remarkable ability to retain complement-fixed antigens on their cell surface for extended periods of time. These retained immune complexes have long been known to provide the antigenic stimulus that drives antibody affinity maturation, but their role in cellular immunity has remained unclear. In this study, we show that FDC-retained antigens are continually sampled by lymph node–resident DCs for presentation to CD8 T cells. This novel pathway of antigen acquisition was detectable when FDCs were loaded with purified antigens bound into classical antigen–antibody immune complexes, as well as after pregnancy, when they are loaded physiologically with antigens associated with the complement-fixed microparticles released from the placenta into maternal blood. In both cases, ensuing antigen presentation was profoundly tolerogenic, as it induced T cell deletion even under inflammatory conditions. These results significantly broaden the scope of FDC function and suggest new ways that the complement system and persistent antigen presentation might influence T cell activation and the maintenance of peripheral immune tolerance.

scholarly journals Agonistic CD40 Antibodies in Cancer Treatment

Cancers ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 1302
Author(s):  
Dijana Djureinovic ◽  
Meina Wang ◽  
Harriet M. Kluger
Keyword(s):  
Dendritic Cells ◽  
T Cell ◽  
Antigen Presentation ◽  
T Cell Activation ◽  
Cell Activation ◽  
Cell Function ◽  
Clinical Development ◽  
The Cancer Genome Atlas ◽  
Early Phase Clinical Trials ◽  
Antigen Presenting

CD40 is expressed on a variety of antigen-presenting cells. Stimulation of CD40 results in inflammation by upregulation of other costimulatory molecules, increased antigen presentation, maturation (licensing) of dendritic cells, and activation of CD8+ T cells. Here we analyzed gene expression data from The Cancer Genome Atlas in melanoma, renal cell carcinoma, and pancreatic adenocarcinoma and found correlations between CD40 and several genes involved in antigen presentation and T cell function, supporting further exploration of CD40 agonists to treat cancer. Agonist CD40 antibodies have induced anti-tumor effects in several tumor models and the effect has been more pronounced when used in combination with other treatments (immune checkpoint inhibition, chemotherapy, and colony-stimulating factor 1 receptor inhibition). The reduction in tumor growth and ability to reprogram the tumor microenvironment in preclinical models lays the foundation for clinical development of agonistic CD40 antibodies (APX005M, ChiLob7/4, ADC-1013, SEA-CD40, selicrelumab, and CDX-1140) that are currently being evaluated in early phase clinical trials. In this article, we focus on CD40 expression and immunity in cancer, agonistic human CD40 antibodies, and their pre-clinical and clinical development. With the broad pro-inflammatory effects of CD40 and its ligand on dendritic cells and macrophages, and downstream B and T cell activation, agonists of this pathway may enhance the anti-tumor activity of other systemic therapies.

Sign in / Sign up

Export Citation Format

Share Document